Skip to main content

Table 2 Incidence of bone metastases and mortality

From: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

Ā 

Clodronate (n = 530)

Placebo (n = 539)

Hazard ratio (95% CI)

P value

Bone metastases (all patients)

Ā Ā Ā Ā 

ā€ƒā€ƒā€ƒ2 years

19 (3.6%)

35 (6.5%)

0.546 (0.312, 0.954)

0.031

ā€ƒā€ƒā€ƒ5 years

51 (9.6%)

73 (13.5%)

0.692 (0.484, 0.990)

0.043

Bone metastases (stage II/III)

Ā Ā Ā Ā 

ā€ƒā€ƒā€ƒn

352

357

Ā Ā 

ā€ƒā€ƒā€ƒ2 years

16 (3.0%)

32 (6.0%)

0.496 (0.272, 0.975)

0.020

ā€ƒā€ƒā€ƒ5 years

39 (7.4%)

64 (11.8%)

0.592 (0.398, 0.882)

0.009

Visceral metastases

Ā Ā Ā Ā 

ā€ƒā€ƒā€ƒ2 years

39 (7.3%)

47 (8.7%)

0.84 (0.55,1.29)

0.428

ā€ƒā€ƒā€ƒ5 years

79 (14.9%)

94 (17.4%)

0.84 (0.62,1.13)

0.241

Visceral metastases (stage II/III)

Ā Ā Ā Ā 

ā€ƒā€ƒā€ƒn

352

357

Ā Ā 

ā€ƒā€ƒā€ƒ2 years

34 (9.7%)

42 (11.8%)

0.81 (0.52,1.28)

0.372

ā€ƒā€ƒā€ƒ5 years

64 (18.2%)

81 (22.7%)

0.77 (0.56,1.07)

0.120

Deaths during follow-up (median follow-up, 5.6 years)

Ā Ā Ā Ā 

ā€ƒā€ƒā€ƒAll patients

98 (18.5%)

129 (23.9%)

0.768 (0.591, 0.999)

0.048

ā€ƒā€ƒā€ƒStage II/III

82 (23.3%)

110 (30.8%)

0.743 (0.558, 0.989)

0.041

  1. CI, confidence interval.